Whippany serves as the home base for the U.S. operations of global life sciences giant Bayer Group.

Bayer U.S. is led by Sebastian Guth, who took the helm last June. Earlier this year, Bayer Pharmaceuticals announced a reshaping and streamlining of its leadership team as it embarked on its next phase of growth. With that, Guth was tapped to also serve as COO of that division, where he is responsible for the company's business operations across all markets worldwide.

"We have decided to dismantle our traditional model with functional silos and many layers of hierarchy. We are replacing it with our new operating model, which has Product and Customer Teams at its center," said Stefan Oelrich, member of the board of management, Bayer AG, and president of Bayer's Pharmaceuticals Division. "These changes within our Leadership Team reflect this new approach to realize the full potential of our growth opportunities."

In May, Bayer released findings that showed its experimental, non-hormonal drug, elinzanetant, reduced the frequency and severity of menopause side effects.

"The robust efficacy and favorable safety profile of elinzanetant reinforces its potential as a non-hormonal treatment for women experiencing menopause," said Dr. Christian Rommel, member of the Executive Committee of Bayer AG's Pharmaceutical Division and global head of research and development. "We look forward to submitting applications to health authorities for marketing authorizations of elinzanetant to treat moderate to severe VMS associated with menopause, building upon our extensive legacy and commitment to women's health care."